Standard BioTools Inc. ( FLDM) Stock. Should you Buy or Sell? $ 3.71
-0.28 (-8.16 %)
Standard BioTools Inc. AnalysisUpdated on 10-09-2022
|Volume Avg.||$956.99 thousand|
|Market Cap||$286.41 M|
|52 Week Range||$2.67 - $7.51|
Standard BioTools Inc. opened the day at $3.71 which is -8.16 % on yesterday's close. Standard BioTools Inc. has a 52 week high of $7.51 and 52 week low of $2.67, which is a difference of $4.84. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $286.41 M and total net profit is $130581000 which means the company is trading at 2.19 times profit to market capitalization. Theoretically, if you were to buy Standard BioTools Inc. for $286.41 M, it would take 15 years to get your money back. Standard BioTools Inc. are in the Diagnostics & Research space which will have a sweet spot and industry standard for net profit multiples.
Fluidigm Corporation Stock Forecast - Is Fluidigm Corporation a Buy or Sell?
|DCF Score||Strong Buy|
|ROE Score||Strong Sell|
|DE Score||Strong Buy|
|PB Score||Strong Buy|
Growth and Value
|Net Profit Margin||-0.939|
Valuing Fluidigm Corporation
|Price Book Value Ratio||12.924||Price To Book Ratio||12.924|
|Price To Sales Ratio||2.299||Price Earnings Ratio||-2.449|
How liquid is Fluidigm Corporation
|Debt Ratio||0.919||Debt Equity Ratio||11.298|
|Long Term Debt To Capitalization||0.861||Total Debt To Capitalization||0.864|
Latest news about Standard BioTools Inc.
Fluidigm Corporation: Investment Opportunity
Fluidigm Corporation (NASDAQ: FLDM) has approved a $250 million investment by Casdin Capital LLC and Viking Global Investors LP with zero-coupon convertible preferred shares with a conversion price of $3.40/share. The investment will significantly advance the Company's mission through new organic and inorganic growth initiatives while optimizing its cost structure.
Fluidigm Corp (NASDAQ: FLDM) expects Q4 FY21 sales of $38.0 million - $38.3 million, exceeding the company's prior guidance of $31 million – $34 million and the analyst estimate of $32.7 million. Base product and service revenue, excluding COVID-19 testing, is expected to be $35.1 million - $35.4 million, +13%–14% Y/Y.
Are these on your list of penny stocks to watch today? The post Hot Penny Stocks To Buy Now?
Fluidigm Corp (NASDAQ: FLDM) posted Q3 revenues of $28.5 million, down 29% Y/Y, missing the consensus of $30.00 million, citing supply chain issues affecting product fulfillment. Fluidigm is undertaking a review of various options to maximize shareholder value, including strategic alternatives, cost & capital structure, and operations and supply chain.
About Standard BioTools Inc.
Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.